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Aims Regulatory T cells (Treg) exert anti-inflammatory and atheroprotective effects in experimental atherosclerosis. Treg can
be induced against specific antigens using immunization strategies associated with clonal restriction. Nodata existon Treg
in combination with clonal restriction of T cells in patients with acute coronary syndromes (ACS).
Methods
and results
Among T cell subsets characterized by flow cytometry, Treg (CD4+CD25+CD127low) were twice as frequent in cor-
onary thrombi compared with peripheral blood. Treg prevailed among T cell subsets identified in coronary thrombi. To
evaluate clonal restriction, genomic DNA was extracted from coronary thrombi and peripheral blood in order to evalu-
ate T cell receptor (TCR) b chain diversity by means of Multi-N-plex PCR using a primer specific for all TCR b V gene
segments and another primer specific for TCRb J gene segments. T cell receptor diversity was reduced in thrombi com-
pared with peripheral blood (intra-individual comparisons in 16 patients) with 8 gene rearrangements in the TCR
common in at least 6 out of 16 analysed coronary thrombi. Compared with age-matched healthy controls (n ¼ 16),
TCR diversity was also reduced in peripheral blood of patients with ACS; these findings were independent of peripheral
T cell numbers.
Conclusion We provide novel evidence for a perturbed T cell compartment characterized by clonal restriction in peripheral blood
and coronary thrombi from patients with ACS. Our findings warrant further studies on Treg as novel therapeutic targets
aimed at enhancing this anti-inflammatory component of adaptive immunity in human atherothrombosis.
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Introduction
Atherothrombosis subsequent to plaque rupture or erosion with
prominent features of inflammation constitutes the underlying
pathophysiology in patients with acute coronary syndromes (ACS).
However, its triggers remain poorly understood and not all rupture-
proneplaques culminate in atherothrombosis.1– 3 We haveprevious-
ly identified monocytes/macrophages as the most abundant inflam-
matory cell type of innate immunity in coronary atherothrombosis,
co-expressing Toll-like receptor (TLR)-4.4 Although less abundant
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in number,T cellsorchestrate the antigen-specific (adaptive) immune
response in atherogenesis with prominent effects mediated by dis-
tinct T cell subsets throughout the stagesof atherosclerosis, including
ACS.2,3,5 –8
Among T cell subsets, regulatory T cells (Treg) exert atheropro-
tective effects and constitute an inherent anti-inflammatory compo-
nent of adaptive immunity.5– 9 Identifying a novel mechanistic link
between Treg immunity and lipid metabolism, we recently demon-
strated that selective depletion of Treg (Foxp3+) impacted on lipid
metabolism mediating hypercholesterolaemia and increased athero-
sclerotic lesions.10 Furthermore, we and others showed that athero-
protective Treg can be induced in response to immunization with
antigen specificity for the apolipoprotein B-100 peptide used in the
vaccine.11 –13 In humans, Treg were found in increased numbers in
lipid-rich, advanced plaques, whereas reduced numbers of circulating
Treg were found in patients with ACS.14–18 From a clinical perspec-
tive, Treg may be an attractive therapeutic target in atherosclerosis
due to their anti-inflammatory effects. However, a better under-
standing of the role of Treg in ACS is necessary.
T cells orchestrateadaptive immunity tomediateanantigen-specific
immuneresponse. Eachcell expresses several copiesof a single antigen
receptorwithauniqueantigen-bindingsite.Thegreat varietyofantigen
specificities in the T cell receptor (TCR) repertoire is generated in the
thymus by random recombination of separate inherited TCR a/b
gene segments termed V(D)J which encode the variable parts of the
heterodimeric receptor. T cell receptor diversity is confined to the
complementarity determining regions (CDRs) as the binding site for
a peptide presented on the major histocompatibility complex by an
antigen-presenting cell (i.e. dendritic cell).19 Recent advances in multi-
plexassay technologymade itpossible tomeasureusage frequenciesof
genesegmentsV(D)Jandenabledetectionand trackingofspecificTCR
sequences expressed by clonally restricted T cells. Compared with
spectratyping which employs only a limited set of V and J primers,
this method enables a more comprehensive analysis that avoids bias
due to transcriptional regulation.20,21
Evidence for an antigen-specific local immune response carried by
T cells in unstable atherosclerotic plaque mandates clonal restriction
of T cells when compared with peripheral blood. Initial reports on
T cells isolated from human atherosclerotic plaques showed a high
TCR diversity indicating a polyclonal origin of T cells.22,23 In circulat-
ing CD4+ CD28null T cells from patients with unstable angina com-
pared with patients with stable coronary artery disease, clonal
restriction of T cells was identified using spectratyping.24 Clonal
restriction of T cells was demonstrated using spectratyping of ather-
ectomy specimens from coronary plaque compared with peripheral
blood mononuclear cells (PBMCs) from patients with ACS and only
to a lesser extent in patients with stable coronary artery disease.25
Similarly, clonal restriction was demonstrated when comparing
carotid plaques with PBMC from asymptomatic and symptomatic
patients with .90% carotid artery stenosis.26
However, so far T cell diversity in thrombi of ACS patients
has not been investigated. The aims of this study, therefore, were
(i) to compare Treg counts in coronary thrombi with PBMC from
patients with ACS, (ii) to compare TCR diversity in coronary
thrombi with PBMC from patients with ACS, (iii) to compare TCR
diversity in PBMC from age-matched healthy subjects with patients
with ACS.
Methods
Characteristics of patients and healthy
subjects
Sixteen patients referred to the University Hospital Zurich, Switzerland,
for coronary angiography with the diagnosis of ACS between 08/2010
and 11/2011 were enrolled as part of a larger cohort study (SPUM-
ACS, clinical trial number NCT01000701). All patients aged 18 years
and older presenting within 72 h after pain onset with the main diagnosis
of ST-elevation myocardial infarction (STEMI) or non-ST elevation myo-
cardial infarction (NSTEMI) were included in the study. Patients had symp-
tomscompatiblewithanginapectoris (chestpain,dyspnoea)andat leastone
of the following inclusion criteria: (i) persistent ST-segment elevation or de-
pression, T inversion or dynamic ECG changes, new LBBB; (ii) evidence of
positive Troponin based on high sensitive TnT measurement (≥14 ng/L)
with rise and/or fall in serial TnT levels. Exclusion criteria comprised docu-
mented active autoimmune disease orneoplasm; stent thrombosis; inability
to comprehend study, less than 1 year of life-expectancy (for non-cardiac
reasons). The Gensini score27 was calculated by two interventional cardi-
ology fellows (inter-observer variability ¼ 17.4) for each of the 16 patients
using the formula severity score × segment location multiplying factor ×
collateral adjustment factor to determine the extent and severity of coron-
ary artery disease in the epicardial coronary arteries. In seven patients, the
Gensini scoredifferedbymore than10pointsbasedonadifferent interpret-
ation of collateral flow/total occlusion and an expert opinion was consulted
from a third experienced senior interventional cardiologist.
Samples from 16 healthy subjects were obtained from a larger cohort
study (SuSa Study, AFSSAPS clinical trial number 2010- A00428-31,
ImmunID) that were recruited between between 07/2010 and 12/2011
atOptimed Clinical Research, Lyon, France. Individuals were included fol-
lowing a detailed medical history, physical examwith vital signs, and blood
draw. Exclusion criteria comprised autoimmune disease or neoplasm,
inability to comprehend study, treatment with corticosteroids or other
immunomodulatory therapy, or vaccination in the three preceding
months. All individuals were older than 18 years of age with birth control
in place for at least 2 months prior to inclusion in women of childbearing
age in the absence of pregnancy or breast feeding. Informed consent was
obtained from all individuals with the approval by the Kantonale Ethik-
Kommission Zurich, Switzerland (EK-1688), for patients with ACS and
the Comite´ de Protection des Personnes CPP Sud-Est III, France
(Numero EudraCT : OL039/Susa), for healthy subjects.
Analyses of blood and coronary thrombi
Laboratory parameters were measured using standard protocols. Indi-
vidual estimated glomerular filtration rate was calculated using the
CKD-EPI formula28 based on serum creatinine, gender, and ethnicity.
Based on the published trials,29,30 coronary thrombi were aspirated
using an Export catheter (Medtronic, Tolochenaz, Switzerland) at the
site of coronary occlusion from patients with ACS undergoing primary
percutaneous coronary intervention (PCI) and were immediately
immersed in phosphate-buffered saline (PBS)-containing vials. Peripheral
blood was sampled from the inguinal arterial sheath from the same
patient and stored in citrate vials. Thrombi and the corresponding periph-
eral blood were treated with 50 mL tissue plasminogen activator (0.001%
Actilysew; Boehringer Ingelheim Pharma GmbH & Co., Ingelheim,
Germany) to remove fibrin in 1 mL 1% Accutasew (PAA Laboratories,
Pasching, Austria), and rotated for 2 h at 378C. Thrombi and blood
were then gently dissociated through a 40 mm pore-size cell strainer
(BD FalconTM) with a rubber syringe plunger and rinsing with ice-cold
PBS. Half of the cell suspensions were separated for Ficoll-paque centri-
fugation and subsequent ImmunTraCkeR bw analysis (ImmunID,
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Grenoble, France), whereas remaining cells were analysed by flow cyto-
metry. In healthy subjects, PBMCs were separated from whole blood
(5 mL EDTA) with a density gradient tube (Uni-Sep, Novamed, Jerusa-
lem, Israel). Peripheral blood mononuclear cells were prepared and sta-
bilized in Easy’IDw stabilization solution provided by ImmunID, Grenoble
following a standard operating procedure.
Analysis of T cell receptor diversity
Human TCR diversity was measured using ImmunTraCkeRbw tests
(ImmunIDTechnologies,Grenoble, France)andperformedasdescribed.31
Peripheral blood mononuclear cells and thrombus samples were frozen
and analysed by ImmunID laboratories. Genomic DNA was extracted
using standard techniques and Multi-N-plex PCR was performed using
an upstream primer specific for all functional members of a given T cell
receptor b V segment and a downstream primer specific for a given T
cell receptor b J segment (international ImMunoGeneTics information
system, www.imgt.org) encoding for the CDR 3 in the human TCR b
chain. This assay allows the simultaneous exhaustive detection of V(D)J
rearrangements in the same reaction expressed as percentage based
on the detected V(D)J combinatorial diversity divided by the expected
maximal diversity (276 gene segments) which corresponds to the theor-
etical combinatorial diversityobtainedwith all rearrangementsof all func-
tional V(D)J genes within the genome. Each Vx–J1, J2, J3, J4, Jn product
was separated as a function of its size. Constel’IDw software (ImmunID
Technologies) was used for further analytical studies, including gener-
ation of three-dimensional repertoire illustration. Numeration and diver-
sity of T cells is presented together through NDLw scoring which enables
to determine a correlation between lymphocyte counts and T cell diver-
sity. A decreased percentage (i.e. a decreased TCR diversity) defines a
state of divpenia (www.divpenia.com). Normal values for TCR b-chain
combinatorial diversity were defined based on a cohort of 16 healthy
volunteers extracted from a larger study (SuSa Study, AFSSAPS clinical
trial number 2010- A00428-31, ImmunID; age range, 42.8–74.9 years;
6 females and 10 males).
Flow cytometry
For flow cytometry, thrombus and peripheral blood-derived cell suspen-
sions obtained from patients with ACS were centrifuged at 200G or
10 min and resuspended in 1 mL of ice-cold FACS buffer (PBS, 1%
foetal calf serum, 0.05% EDTA) with FcR block (Human TruStain FcX,
Biolegend, San Diego, CA, USA). Cells were labelled for 1 h at 48C
with monoclonal antibodies for extracellular staining of CD3, CD4,
CD8, CD28, and a three-color reagent (CD4, CD25, CD127) for identi-
fication ofTreg (all fromBD Biosciences, San Jose, CA, USA) and analysed
on a FACScalibur (BD Biosciences). Subpopulation analyses were per-
formed using SSC/FSC scatters, differentiating lymphocyte, monocytes,
and granulocyte gates (quadrant analysis). Mouse IgG1 was used as
isotype control and the proportion of positive cells per lymphocyte
gate were determined.
Statistical analysis
For comparisons of continuous and categorical data, we used the non-
parametric Mann–Whitney U-test and the Pearson Chi-square test, re-
spectively. Intra-individual comparisons of distributions of combinatorial
diversity and percentages of cell counts are the result of Wilcoxon signed
rank test for paired data. Unless otherwise indicated, data are shown as
mean+ SEM or relative and absolute frequencies. Pearson’s correlation
coefficient was determined for the Gensini score (mean) and TCR diver-
sity in PBMC and thrombi, respectively. A two-sided P-value of ,0.05
was considered significant.
Results
Clinical characteristics of patients with
acute coronary syndromes and healthy
subjects
Pairsof coronary thrombi andperipheralbloodwereobtained from16
patients with ACS using an aspiration catheter as part of the PCI for a
native coronary culprit lesion. Among these, 12 patients were diag-
nosed with STEMI, 4 patients with NSTEMI, 11 patients were symp-
tomatic for ,24 h, 4 patients had symptoms for 24–48 h and 1
patient for 48–72 h. For theevaluationofTCRb chain diversity inper-
ipheral blood, 16 patients with ACS were compared with 16 healthy
age-matched subjects. The clinical, demographic, and laboratory char-
acteristics of patients with ACS and matched healthy subjects are sum-
marized in Table 1. Compared with healthy subjects, patients with ACS
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Table 1 Clinical, demographic, and laboratory
characteristics of patients and healthy subjects
ACS Healthy P-value
Age (years) 58.9+2.3 58.7+2.3 n.s.
Male gender (%) 15 (94) 10 (63) n.s
Caucasian ethnicity (%) 16 (100) 16 (100) n.s.
Leucocyte count (103/mL) 11.6+1.5 5.8+0.3 P ≤ 0.001
Lymphocyte count (103/mL) 3.2+1.2 1.6+0.08 n.s.
Erythrocytes (106/mL) 4.3+0.2 4.5+0.1 n.s.
Platelets (103/mL) 279+25 219+8 P, 0.05
Total cholesterol (mmol/L) 5.1+0.4 5.6+0.3 n.s.
Baseline glucose (mmol/L) 9.0+1.7 5.2+0.08 P ≤ 0.01
Serum creatinine (mmol/L) 79.9+6.3 72.1+2.7 n.s.
eGFR (mL/min) 90.1+4.9 92.3+2.4 n.s.
BMI (kg/m2) 28.4+2.0 24.6+1.1 n.s.
Gensini Score 39.7+5.7 0 P ≤ 0.001
Cardiovascular risk factors
Hypercholesterolaemia 8 (50) 0 P ≤ 0.01
Hypertension (%) 4 (25) 0 P, 0.05
Diabetes (%) 2 (13) 0 n.s.
Smoking (current, %) 7 (44) 0 P ≤ 0.01
Previous medical history
Previous MI 3 (19) 0 n.s.
Previous PCI 2 (13) 0 n.s.
Medications
Aspirin (%) 16 (100) 0 P ≤ 0.001
Statins (%) 4 (25) 0 P, 0.05
ACE-I/ARB (%) 2 (13) 0 n.s.
b-Blockers (%) 3 (19) 0 n.s.
Nitrates (%) 15 (94) 0 P ≤ 0.001
Calcium antagonists (%) 0 0 –
Diuretics (%) 1 (6) 0 n.s.
Values are shown as mean+ SEM or absolute and relative frequencies (in brackets
with respect to n ¼ 16 patients), respectively.
N ¼ 12–16; n.s. non-significant. ACE-I/ARB, angiotensin converting
enzyme-inhibitor/angiotensin receptor blocker; aspirin comprises oral and
intravenous formulation; BMI, body mass index; eGFR, estimated glomerular
filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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had increased leucocyte and platelet counts, elevated glucose concen-
tration in peripheral blood, presence of coronary artery disease,
cardiovascular risk factors, and received medications.
IncreasedTregcounts incoronary thrombi
compared with peripheral blood in
patients with acute coronary syndromes
Toevaluate T cell subset distribution, flowcytometry wasperformed
for phenotypic characterization of coronary thrombi compared
with PBMC from patients with ACS. Overall CD3+ T cell content
was unaltered and no difference was detected for T helper cells
(CD4+ CD3+ CD82), but for a trend to numerical reduction vs.
peripheral blood (Figure 1A and B). In contrast, Treg (CD4+
CD25+CD127low) were significantly increased by 2.2-fold in coron-
ary thrombi (Figure 1C). Cytotoxic T cells (CD8+ CD3+ CD42),
CD4+ CD3+ CD28null T cells and double negative (CD42 CD82
CD3+) T cells were found in similar numbers in coronary
thrombi and PBMC (Figure 1D–F). Supplementary material online,
Figures S1–S6 show representative graphs on how FACS analysis
for individual cell subsets was performed. Supplementary material
online, Figure S7 shows a representative immunostaining of CD3+
T cells.
Figure1 Treg as prominent T cell subset in coronary thrombi vs. peripheral blood frompatients with ACS. Flowcytometry of coronary thrombus
and PBMC from patients with ACS. Double-staining for T cell subtypes (CD3 with CD8 or CD4, respectively). (A) T cells (CD3+). (B) T helper cells
(CD4+ CD3+CD82). (C) Regulatory T cells (CD4+ CD25+ CD127low). (D) Cytotoxic T cells (CD8+ CD3+ CD42). (E) CD4+CD3+ CD28null
T cells. (F) Double-negative T cells (CD4null CD8null CD3+). The bottom and top of the box represent the first and third quartiles (Q1, Q3), and the
band inside the box is the median. The whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range
(IQR ¼ Q32Q1) from the box, with individual outliers shown beyond the whisker; n ¼ 9–12; *P ¼ 0.0098.
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Decreased T cell receptor diversity in
coronary thrombi compared with
peripheral blood in patients with acute
coronary syndromes
Pairwise intra-individual comparisons of coronary thrombi demon-
strated a markedly reduced TCR diversity in coronary thrombi vs.
PBMC (reduction by 0.28-fold), shown in Figure 2A–C. Among
V(D)J gene segments identified in coronary thrombi from 16 patients
with ACS, 8 rearrangements were found in common in at least 6
thrombi from individual patients (Table 2). These gene rearrange-
ments are Vbeta18-J2.3, which is the most frequent (8/16);
Vbeta05-J2.7 and Vbeta25-J2.6, both found in common in 7/16
samples; Vbeta27-J2.7, Vbeta24-J2.3, Vbeta24-J2.5, Vbeta15-J2.4,
and Vbeta19-J2.5 were found in common in 6/16 samples (IMGT no-
menclature). In turn, in peripheral blood from patients with ACS,
Vbeta05-J2.7 was the most frequently detected gene rearrangement
(13/16). Interestingly, Vbeta05-J2.7 was less common in coronary
thrombi compared with PBMC (Table 2). T cell receptor diversity
was only weakly correlated with the extent and severity of epicardial
coronary artery disease as assessed by the Gensini score (Supple-
mentary material online, Figure S8). Pearson’s correlation coefficient
for the comparison of the Gensini score (mean) with TCR diversity in
PBMC was20.418 and20.058 for the comparison of the score with
TCRdiversity in coronary thrombus, respectively.Theseassociations
were not significant.
Reduced T cell receptor diversity in
circulating T cells of patients with acute
coronary syndromes compared with
healthy subjects
T cell receptor diversity was measured using genomic DNA isolated
from PBMCs from 16 healthy subjects and PBMCs from 16 patients
with ACS. Compared with matched healthy subjects, patients with
ACS had a profoundly reduced TCR diversity in peripheral blood (re-
duction by 0.36-fold), shown in Figure 3A–C. Importantly, reduced
TCR diversity did not correlate with overall lymphocyte cell
Figure 2 Reduced T cell receptor diversity in coronary thrombus vs. peripheral blood from patients with ACS. Intra-individual comparisons of
TCR diversity expressed as percentage of 276possible V(D)J gene segment rearrangements in the human TCRb chain (hTRB) in coronary thrombus
vs. PBMC (A). Bars indicate means; **P ¼ 0.001. Representative 3-D plots of human TCR b chain diversity in an individual patient with ACS derived
from PBMC (B) and coronary thrombus (C ).
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number in peripheral blood from patients with ACS and healthy sub-
jects (Figure 3D).
Discussion
The present study confers the following key findings: first, we identi-
fied Treg as the major T cell subset in aspirated coronary thrombus
adjacent to the culprit lesion in patients with ACS. Second, we
found a restricted TCR diversity within coronary thrombi compared
with peripheral blood of patients with ACS. Third, we show a mark-
edly reduced TCR diversity also in peripheral blood of patients with
ACS compared with healthy age-matched subjects.
We previously showed an increased immune response at the site
of coronaryocclusion in patientswith ACScomparedwith peripheral
blood, demonstrating elevated levels of serum amyloid A, interleukin
(IL)-6,32 myeloid-related protein 8/14,33 and expression of TLR-4 on
monocytes as part of innate immunity.4 The current study expanded
these previous findings to T cells. Analysis of adaptive immunity
carried by T cell subsets in patients with ACS was performed by com-
paring coronary thrombi with peripheral blood intra-individually and
peripheral blood from healthy subjects.
Treg were reported in increased numbers in lipid-rich, advanced
plaques, whereas reduced numbers of circulating Treg were found
in patients with an ACS.14– 18 This decrease in the circulating Treg
pool is currently unclear as it may be due to either a global Treg
defect or increased redistribution between the blood and local
sites of inflammation.34 Interestingly, the latter study18 found
reduced circulating Treg in patients with unstable angina, but
increasedcirculating Treg in patients with acute myocardial infarction
(AMI). This may be attributable to insufficient Treg recruitment to
the site of the culprit lesion in patients with AMI unlike in unstable
angina where sufficient influx of Treg is maintained to control the in-
flammatory reaction in the lesion.34 In contrast, we herein demon-
strated a 2.2-fold increase in Treg counts in coronary thrombus
adjacent to the ruptured plaque compared with peripheral blood,
suggesting efficient redistribution of the circulating Treg pool to in-
flammatory sites in patients with ACS. Furthermore, we found 8
TRB VJ rearrangements common in at least 6 of the 16 analysed
thrombus samples. Treg accumulation in non-lymphoid tissues (cor-
onary thrombus in our study) is shaped by several mechanisms in-
cluding migration and retention of circulating Treg as well as
expansion of Treg clones specific for tissue-specific antigens.35 The
local chemokine and cytokine milieu and expression of antigens spe-
cific for the tissue promote chemotaxis and clonal expansion of Treg.
Temporal changes in these factors may impact on the amount of Treg
detected by flow cytometry in our study. It is possible that the in-
crease in Treg in coronary thrombi found in the current study reflects
a local compensatory response to attenuate inflammation in the sur-
rounding pro-inflammatory milieu characterizedbyelevated concen-
trations of pro-inflammatory cytokines in coronary blood distal to
the occluding coronary thrombus.4 However, intra-individual com-
parison of TCR diversity in coronary thrombus vs. peripheral
blood was reduced in all but three patients in the present study
(Figure 2A), demonstrating a consistent pattern of clonal restriction
in thrombus-resident T cells, the majority of which are likely Treg.
T cell receptor diversity both in peripheral blood and coronary
thrombi, respectively, was not associated with the extent and sever-
ity of coronary artery disease in our study as assessed by the Gensini
score. This finding suggests that the observed restricted TCR diver-
sity in coronary thrombi may reflect differential trapping of antigen-
primed T cells from the circulating T cell pool, unrelated to the
burden of underlying atherosclerotic disease. To provide definitive
cues to the origin of Treg in coronary thrombi, future work should
analyse Treg in atherothrombosis using a suitable experimental
model such as the DEREG mouse model10 to track labelled Treg in
secondary lymphoid organs, atherosclerotic lesions, and thrombus,
respectively. Along those lines, our data are in favour of a post hoc al-
teration of T cell subsets as a consequence of the ACS rather than a
predisposing factor reflecting an a priori immune imbalance.
The concept of expanding antigen-specific Treg to diminish vascu-
lar inflammation and prevent atherothrombotic clinical events by im-
munotherapy7 is appealing. Using an immunization strategy, we and
others identified antigen-specific Treg as a critical component of
atheroprotection in mice.11 –13 However, more data on the origin,
recruitment, and kinetics of Treg during myocardial infarction are
needed before such an approach can be evaluated in a clinical trial.
The recently completed phase II GLACIER study (NCT01258907)
reported no change in inflammatory activity in an index arterial
vessel after 12 weeks of treatment with a monoclonal antibody tar-
geting oxidized forms of LDL compared with controls, as measured
by FDG-PET/CT imaging ([18F ]-2-deoxyglucose positron emission-
tomography/computed tomography but showed a good safety
profile. Pending full publication of the data, the choice of primaryend-
point, treatment duration, and patients appear pivotal for future trials
to address efficacy of immunotherapy in atherosclerotic disease.7
Limitations
We could not perform cell-sorting and subsequent repertoire ana-
lysis for TCR diversity in Treg only as coronary thrombi are very
small with very few T cells present.
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Table 2 T cell receptor b gene segment
rearrangements in patients with an acute coronary
syndrome
V-J rearrangement PBMC Thrombus P-value
Vbeta18-J2.3 7 (44) 8 (50) n.s.
Vbeta05-J2.7 13 (81) 7 (44) P ¼ 0.028
Vbeta25-J2.6 3 (19) 7 (44) n.s.
Vbeta27-J2.7 11 (69) 6 (38) n.s.
Vbeta24-J2.3 10 (63) 6 (38) n.s.
Vbeta24-J2.5 8 (50) 6 (38) n.s.
Vbeta15-J2.4 6 (38) 6 (38) n.s.
Vbeta19-J2.5 3 (19) 6 (38) n.s.
Vbeta04-J2.3 9 (56) 5 (31) n.s.
Vbeta05-J2.5 8 (50) 5 (31) n.s.
Vbeta24-J2.4 7 (44) 5 (31) n.s.
Vbeta20-J2.6 3 (19) 5 (31) n.s.
All values are shown as absolute and relative frequencies (in brackets with respect to
n ¼ 16 patients), respectively. n.s., non-significant by the Pearson Chi-square test.
R. Klingenberg et al.1046
Summary and conclusions
Our study is the first to report a restricted TCR diversity in a mark-
edly increased cell pool of leucocytes in peripheral blood from
patients with ACS when compared with age-matched healthy sub-
jects. Together with the profound reduction in TCR diversity identi-
fied in coronary thrombi, these findings imply an antigen-specific
immune response carried by T cells in patients with ACS. Interesting-
ly, patients with rheumatoid arthritis also show a reduced TCR diver-
sity in circulating T cells compared with healthy individuals.36 Our
finding adds to the shared features between rheumatoid arthritis
and clinical atherosclerosis, suggesting similar autoimmune features
in the pathogenesis of atherothrombosis.
In conclusion, we demonstrate a perturbed T cell compartment
characterized by clonal restriction of T cells in both peripheral
blood and coronary thrombi of patients with ACS. Our data
provide novel evidence for antigen-specific adaptive immunity in
atherothrombosis with Treg as the prominent T cell subset.
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